Reduction in Exacerbations Remains the Top Driver of Physician Prescribing Choice in Moderate to Severe Asthma, According to Findings from Decision Resources Group
May 1, 2014 – Burlington, Mass. –
Decision Resources Group finds that 90 percent of surveyed U.S. payers indicated a willingness to pay a premium-price for a novel therapy with substantially greater improvements in reducing exacerbations than Genentech/Novartis’s Xolair in the treatment of severe asthma. Surveyed U.S. and European pulmonologists agree that reduction in rate of exacerbations is the attribute that most influences prescribing decisions in moderate to severe asthma. Clinical data and the opinions of interviewed thought leaders indicate that GlaxoSmithKline’s Bosatria and Roche/Genentech/Chugai’s lebrikizumab have a potential to partially fulfill this unmet need.
Other key findings from the Decision Base report entitled Asthma (Moderate to Severe): Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Pulmonologists and Payers Expect of an Emerging Therapy?
Unmet need: Surveyed pulmonologists indicate that a therapy offering a greater improvement in quality of life is one of the highest unmet needs in moderate to severe asthma. No emerging therapies are positively differentiated from the market leader, GlaxoSmithKline’s Advair/Seretide/Adoair, on this attribute, based on clinical data and according to the opinions of interviewed thought leaders.
Opportunities for differentiating novel therapies: Less-frequent administration is the delivery attribute with the greatest opportunity for positively differentiating novel therapies entering the asthma market. This need will be fulfilled by all emerging therapies profiled in our report, including GlaxoSmithKline/Theravance’s Breo/Relvar, Boehringer Ingelheim/Pfizer’s Spiriva, Bosatria, Cephalon/Teva’s Cinqiul and lebrikizumab. Breo/Relvar and Spiriva are once-daily inhalers, in contrast to the twice-daily options currently available. All of the late-stage emerging biologics in development for the treatment of asthma are currently dosed once every four weeks in their respective clinical trials, similar to Xolair and much less frequently than oral or inhaled therapies.
Efficacy versus price: Results of a conjoint analysis indicate that in severe asthma, U.S. pulmonologists are willing to prescribe a novel therapy with strong efficacy in reductions in exacerbations and oral corticosteroid dose even if that drug carries a high price premium over Xolair.
Comments from Decision Resources Group Analyst Eun-Jin Yang, Ph.D.:
About Decision Resources Group
“Findings from our survey of physicians and payers emphasize that although current treatments are sufficient for a substantial portion of the asthma population, moderate to high unmet needs remain for many patients with moderate to severe asthma. Particularly, emerging agents that can offer greater reductions in exacerbations and oral corticosteroid use over currently available therapies may reap the benefit as preferred choices in physician prescribing and reimbursement.”
“Even though less-frequent administration received the highest level of unmet need among delivery attributes, surveyed U.S. and European pulmonologists assigned it only a low to moderate level of unmet need, respectively. This suggests that, at least for U.S. pulmonologists, it may merely be an issue of convenience and not a major priority.”
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.